Inhibikase Therapeutics Q2 2024 Earnings Report $2.24 -0.05 (-2.18%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Inhibikase Therapeutics EPS ResultsActual EPS-$0.66Consensus EPS -$0.58Beat/MissMissed by -$0.08One Year Ago EPSN/AInhibikase Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInhibikase Therapeutics Announcement DetailsQuarterQ2 2024Date8/14/2024TimeN/AConference Call ResourcesIKT Earnings History Remove Ads Inhibikase Therapeutics Earnings HeadlinesInhibikase Therapeutics (IKT) Receives a Hold from H.C. WainwrightMarch 29 at 4:22 AM | markets.businessinsider.comHC Wainwright Reiterates "Neutral" Rating for Inhibikase Therapeutics (NYSE:IKT)March 29 at 3:43 AM | americanbankingnews.comGame Over for Tesla?Tesla is down 50% from its high... Our research indicates investors are waking up to the fact that Tesla is no longer Musk's #1 priority. His real goal is political power - and his private AI firm xAI. He recently bought over $1 billion worth of AI chips from NVIDIA... And is about to spend $5 billion on yet another data center for xAI.March 31, 2025 | Behind the Markets (Ad)Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityMarch 27, 2025 | globenewswire.comInhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSOFebruary 24, 2025 | markets.businessinsider.comInhibikase Announces Expansion of Senior Leadership TeamFebruary 24, 2025 | globenewswire.comSee More Inhibikase Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibikase Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibikase Therapeutics and other key companies, straight to your email. Email Address About Inhibikase TherapeuticsInhibikase Therapeutics (NYSE:IKT), a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.View Inhibikase Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
